Illumina, Inc. with ticker code (ILMN) have now 22 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges between $253.00 and $100.00 suggesting an average Analsyt target price of $147.91. Given that the stocks previous close was at $113.70 this would imply there is now a potential upside of 30.1%. The 50 day moving average now sits at $116.87 and the 200 day MA is $127.99. The total market capitalization for the company now stands at 17.49B. The stock price is currently at: $109.82 USD
The potential market cap would be $22,758,009,212 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of -, revenue per share of $28.39 and a -0.5% return on assets.
Illumina, Inc. is a provider of sequencing- and array-based solutions for genetic and genomic analysis. The Company operates through two segments: Core Illumina and GRAIL. Its Core Illumina segment offers products and services that serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Its GRAIL segment is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed to accelerate and simplify genetic analysis. Its BaseSpace Informatics Suite integrates directly with its sequencing instruments, allowing customers to manage their biological sample and sequencing runs, process and analyze the raw genomic data, and derive results. Its BeadArray technology combines microscopic beads and a substrate in a proprietary manufacturing process to produce arrays that can perform various assays simultaneously.
